(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.48%) $79.64
(0.61%) $2.32
(0.62%) $2 354.80
(0.74%) $28.58
(0.46%) $995.40
(0.05%) $0.928
(-0.16%) $10.85
(0.02%) $0.799
(0.00%) $92.54
0.31% INR 1 450.60
Live Chart Being Loaded With Signals
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally...
Stats | |
---|---|
आज की मात्रा | 12 950.00 |
औसत मात्रा | 19 823.00 |
बाजार मूल्य | 23.99B |
EPS | INR8.01 ( 2024-05-02 ) |
अगली कमाई की तारीख | ( INR0 ) 2024-07-25 |
Last Dividend | INR12.00 ( 2023-07-21 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 27.33 |
ATR14 | INR2.77 (0.19%) |
मात्रा सहसंबंध
RPG Life Sciences Limited सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
RPG Life Sciences Limited सहसंबंध - मुद्रा/वस्त्र
RPG Life Sciences Limited वित्तीय
Annual | 2023 |
राजस्व: | INR5.82B |
सकल लाभ: | INR2.48B (42.66 %) |
EPS: | INR53.01 |
FY | 2023 |
राजस्व: | INR5.82B |
सकल लाभ: | INR2.48B (42.66 %) |
EPS: | INR53.01 |
FY | 2022 |
राजस्व: | INR5.13B |
सकल लाभ: | INR3.42B (66.68 %) |
EPS: | INR40.90 |
FY | 2022 |
राजस्व: | INR4.37B |
सकल लाभ: | INR2.87B (65.64 %) |
EPS: | INR31.13 |
Financial Reports:
No articles found.
RPG Life Sciences Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR9.60 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR12.00 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR1.200 | 2008-08-11 |
Last Dividend | INR12.00 | 2023-07-21 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 16 | -- |
Total Paid Out | INR51.04 | -- |
Avg. Dividend % Per Year | 1.03% | -- |
Score | 3.1 | -- |
Div. Sustainability Score | 7.98 | |
Div.Growth Potential Score | 5.56 | |
Div. Directional Score | 6.77 | -- |
Year | Amount | Yield |
---|---|---|
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR2.40 | 0.61% |
2019 | INR2.40 | 1.01% |
2020 | INR4.00 | 1.26% |
2021 | INR7.20 | 1.92% |
2022 | INR9.60 | 1.57% |
2023 | INR12.00 | 1.41% |
2024 | INR0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RAINBOW.NS | Dividend Junior | 2023-06-22 | Annually | 3 | 0.21% | |
KIRLOSBROS.NS | Dividend Junior | 2023-07-25 | Annually | 17 | 0.99% | |
EMMBI.NS | Dividend Junior | 2023-08-04 | Annually | 14 | 0.28% | |
AKSHARCHEM.NS | No Dividend Player | 2023-09-20 | Annually | 7 | 0.34% | |
SUPRIYA.NS | Dividend Junior | 2023-09-15 | Annually | 3 | 0.10% | |
NBIFIN.NS | Dividend Junior | 2023-08-11 | Sporadic | 8 | 0.01% | |
HSCL.NS | Dividend Knight | 2023-06-09 | Annually | 18 | 0.22% | |
CASTROLIND.NS | Dividend Knight | 2023-08-08 | Semi-Annually | 22 | 4.14% | |
RPPL.NS | Dividend Junior | 2023-08-24 | Annually | 6 | 0.31% | |
LICHSGFIN.NS | Dividend Junior | 2023-08-18 | Annually | 23 | 1.85% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.151 | 1.500 | 6.99 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.171 | 1.200 | 4.30 | 5.16 | [0 - 0.3] |
returnOnEquityTTM | 0.259 | 1.500 | 8.23 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.28 | 0.800 | 3.62 | 2.90 | [1 - 3] |
quickRatioTTM | 1.342 | 0.800 | 6.81 | 5.45 | [0.8 - 2.5] |
cashRatioTTM | 0.278 | 1.500 | 9.56 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 370.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 15.22 | 2.00 | 4.93 | 9.85 | [0 - 30] |
freeCashFlowPerShareTTM | 15.22 | 2.00 | 2.39 | 4.78 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.557 | 1.000 | 4.06 | 4.06 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.197 | 1.000 | 8.05 | 8.05 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 1.135 | 0.800 | 5.77 | 4.61 | [0.5 - 2] |
Total Score | 7.98 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 27.68 | 1.000 | 7.30 | 0 | [1 - 100] |
returnOnEquityTTM | 0.259 | 2.50 | 8.86 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 15.22 | 2.00 | 4.93 | 4.78 | [0 - 30] |
dividendYielPercentageTTM | 0.817 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 15.22 | 2.00 | 4.93 | 9.85 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.965 | 1.500 | 6.90 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0432 | 1.000 | -1.419 | 0 | [0.1 - 0.5] |
Total Score | 5.56 |
RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmentics, anti-convulsant, anti-spasmodic, etc. It also provides generics primarily in area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular, diabetology, orthopedics, neuropsychiatry, respiratory, nutritional, general, urology, anti-diabetic, anti-dengue, vitamins and minerals, gynecology and pediatrics, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is headquartered in Mumbai, India. RPG Life Sciences Limited is a subsidiary of Nucleus Life Trust.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं